Therapeutic Solutions International (TSOI) 10-K 21 May 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	May 14, 2020	Jun. 30, 2019
Details
Registrant CIK	0001419051
Fiscal Year End	--12-31
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	000-54554
Entity Registrant Name	Therapeutic Solutions International, Inc.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	45-1226465
Entity Address, Address Line One	4093 Oceanside Boulevard, Suite B
Entity Address, City or Town	Oceanside
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92056
Entity Address, Address Description	Address of principal executive offices, including zip code
City Area Code	760
Local Phone Number	295-7208
Phone Fax Number Description	Registrant's telephone number, including area code
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 1,192,453
Share Price			$ 0.015
Entity Common Stock, Shares Outstanding		1,656,544,305
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 26,410	$ 22,397
Restricted cash	10,187	10,173
Accounts receivable	2,904	0
Inventory	5,180	0
Prepaid expenses and other current assets	89,379	113,521
Right-of-use asset	5,619	0
Total current assets	139,679	146,091
Assets, Noncurrent	171,322	60,840
Total assets	311,001	206,931
Current liabilities:
Accounts payable	324,936	320,812
Accounts payable-related parties	12,715	7,981
Accrued expenses and other current liabilities	505,072	717,723
Lease liability	5,619	0
Convertible notes payable, net of discount of $105,525 and $105,556, at December 31, 2019 and 2018, respectively	38,475	45,784
Notes payable-related parties, net	937,528	458,487
Derivative Liability, Current	521,700	466,612
Total current liabilities	2,346,045	2,017,399
Commitments and contingencies	0	0
Shareholders' deficit:
Preferred shares	0	0
Common shares	1,614,628	1,011,063
Additional paid-in capital	5,183,228	4,314,047
Accumulated deficit	(8,832,900)	(7,135,578)
Total shareholders' deficit	(2,035,044)	(1,810,468)
Total liabilities and shareholders' deficit	$ 311,001	$ 206,931

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Debt Instrument, Unamortized Discount, Current	$ 105,525	$ 105,556
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	3,500,000,000
Common Stock, Shares, Issued	1,614,627,811	1,011,063,182
Common Stock, Shares, Outstanding	1,614,627,811	1,011,063,182

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Net sales	$ 27,495	$ 3,484
Cost of goods sold	3,015	2,157
Gross profit	24,480	1,327
Operating Expenses
General and administrative	70,537	408,364
Salaries, wages, and related costs	305,133	415,072
Stock compensation	355,000	0
Consulting fees	181,374	112,877
Legal and professional fees	127,917	189,853
Research and development	27,685	74,970
Total operating expenses	1,067,646	1,201,136
Operating Income (Loss)	(1,043,166)	(1,199,809)
Other income (expense):
Loss on derivative liability	(352,934)	(388,121)
Change in fair value of derivative liabilities	49,521	(37,230)
Interest expense	(350,743)	(241,752)
Total other income (expense)	(654,156)	(667,103)
Net Income (Loss)	$ (1,697,322)	$ (1,866,912)
Basic and diluted net loss per common share	$ 0	$ 0
Basic and diluted weighted-average common shares outstanding	1,284,150,496	896,851,647

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2017	$ 806,501	$ 3,147,811	$ (5,268,666)	$ (1,314,354)
Shares, Outstanding, Beginning Balance at Dec. 31, 2017	806,501,000
Stock Issued During Period, Value, Issued for Services	$ 77,500	545,750	0	623,250
Stock Issued During Period, Shares, Issued for Services	77,500,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 66,062	432,486	0	498,548
Stock Issued During Period, Shares, Conversion of Convertible Securities	66,062,182
Stock Issued During Period, Value, New Issues	$ 61,000	188,000	0	249,000
Stock Issued During Period, Shares, New Issues	61,000,000
Beneficial conversion feature on note payable				0
Net Income (Loss)	$ 0	0	(1,866,912)	(1,866,912)
Shares, Outstanding, Ending Balance at Dec. 31, 2018	1,011,063,182
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2018	$ 1,011,063	4,314,047	(7,135,578)	(1,810,468)
Stock Issued During Period, Value, Issued for Services	$ 200,000	268,000	0	468,000
Stock Issued During Period, Shares, Issued for Services	200,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 235,562	526,702	0	762,264
Stock Issued During Period, Shares, Conversion of Convertible Securities	235,561,296
Stock Issued During Period, Value, New Issues	$ 72,033	4,397	0	76,430
Stock Issued During Period, Shares, New Issues	72,033,333
Common stock issued for a license, Value	$ 95,970	57,582	0	153,552
Common stock issued for a license, Shares	95,970,000
Beneficial conversion feature on note payable	$ 0	12,500	0	12,500
Net Income (Loss)	$ 0	0	(1,697,322)	(1,697,322)
Shares, Outstanding, Ending Balance at Dec. 31, 2019	1,614,627,811
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2019	$ 1,614,628	$ 5,183,228	$ (8,832,900)	$ (2,035,044)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net Income (Loss)	$ (1,697,322)	$ (1,866,912)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to consultants	113,000	303,750
Stock-based compensation to related parties	355,000	319,500
Loss on derivative liabilities	352,934	388,121
Change in fair value of derivative liabilities	(49,521)	37,230
Amortization of debt discount	278,593	194,985
Patent amortization	6,591	0
Changes in operating assets and liabilities:
Accounts receivable	(2,904)	0
Inventory	(5,180)	1,515
Prepaid expenses and other current assets	60,621	(112,467)
Right-of-use asset	(5,619)	(47,086)
Accounts payable	4,122	(22,998)
Accounts payable - related parties	4,734	7,981
Accrued expenses and other current liabilities	268,618	327,209
Lease liability	5,619	0
Net cash used in operating activities	(310,714)	(469,172)
Cash flows from financing activities:
Payments on notes payable to related party	(3,689)	(2,460)
Proceeds from convertible notes payable to related party	25,000	0
Payments on convertible notes payable	(33,000)	0
Proceeds from convertible notes payable	250,000	245,000
Proceeds from sale of common stock	76,430	249,000
Net cash provided by financing activities	314,741	491,540
Net increase (decrease) in cash	4,027	22,368
Cash and cash equivalents	32,570	10,202
Cash and cash equivalents	36,597	32,570
Supplemental disclosure of cash flow information
Cash paid for interest	21,581	4,608
Income Taxes Paid	0	1,600
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable	0	27,000
Debt discount recorded in connection with derivative liability	250,000	245,000
Common stock issued in conversion of convertible notes payable and interest	762,264	498,548
Beneficial conversion feature on note payable	12,500	0
Common stock issued in payment of license agreement	153,552	0
Formalization of accrued salary into related party note	430,715	0
Accrued interest added to principal	35,614	0
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	26,410	22,397
Restricted cash included in other assets	10,187	10,173
Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows	$ 36,597	$ 32,570

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2019
Notes
Note 1 - Nature of Business	Note 1 – Nature of business Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation. Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. Nutraceutical Division Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. Management does not expect existing cash as of December 31, 2019 or as of March 31, 2020 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2019, the Company has incurred losses totaling $8.8 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Notes
Note 2 - Basis of Presentation	Note 2 - Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) 2) 3) 4) 5) ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Wholesale policies: Delivery. Purchase Price & Payments. Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Returns. Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2019 and 2018, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $521,700 and $466,612 at December 31, 2019 and 2018, respectively. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2018, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2019 and 2018: Balance, December 31, 2017 $ 107,769 Issuance of new derivative liabilities 633,122 Conversions to paid-in capital (311,509) Change in fair market value of derivative liabilities 37,230 Balance, December 31, 2018 466,612 Issuance of new derivative liabilities 602,934 Conversions to paid-in capital (498,325) Change in fair market value of derivative liabilities (49,521) Balance, December 31, 2019 $ 521,700 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2019 and 2018, a total of 181,588,903 and 226,902,346 , Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. During the years ended December 31, 2019 and 2018, there was no depreciation or amortization expense as all fixed assets have been fully depreciated. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2019 and 2018 was $6,591 and $0, respectively. Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $27,685 and $74,970 for the years ended December 31, 2019 and 2018, respectively. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $5,619 as of December 31, 2019. Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Note 3 - Restricted Cash

Note 3 - Restricted Cash	12 Months Ended
	Dec. 31, 2019
Notes
Note 3 - Restricted Cash	Note 3 – Restricted cash Included in current assets is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2020, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Note 4 - Prepaid expense and ot

Note 4 - Prepaid expense and other current assets	12 Months Ended
	Dec. 31, 2019
Notes
Note 4 - Prepaid expense and other current assets	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: December 31, 2019 December 31, 2018 Prepaid consulting $ 88,261 $ 111,655 Insurance - 848 Prepaid costs 1,118 1,018 Total $ 89,379 $ 113,521

Note 5 - Fixed assets

Note 5 - Fixed assets	12 Months Ended
	Dec. 31, 2019
Notes
Note 5 - Fixed assets	Note 5 – Fixed assets Fixed assets consist of the following: December 31, 2019 December 31, 2018 Computer hardware $ 10,747 $ 10,747 Office furniture and equipment 3,639 3,639 Shipping and other equipment 1,575 1,575 Total 15,961 15,961 Accumulated depreciation (15,961) (15,961) Property and equipment, net $ - $ - Depreciation expense was $0 for December 31, 2019 and 2018.

Note 6 - Other Assets

Note 6 - Other Assets	12 Months Ended
	Dec. 31, 2019
Notes
Note 6 - Other Assets	Note 6 – Other assets Other assets consist of the following: December 31, 2019 December 31, 2018 Prepaid consulting $ 20,238 $ 56,717 Deposit 4,123 4,123 Licenses, net 146,961 - Total $ 171,322 $ 60,840 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: December 31, 2019 December 31, 2018 License $ 153,552 $ - Accumulated amortization (6,591) - Licenses, net $ 146,961 $ - As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI.

Note 7 - Convertible Notes Paya

Note 7 - Convertible Notes Payable	12 Months Ended
	Dec. 31, 2019
Notes
Note 7 - Convertible Notes Payable	Note 7 – Convertible notes payable On January 3, 2018, February 27, 2018, May 1, 2018, June 5, 2018, July 2, 2018, August 6, 2018, October 3, 2018, November 15, 2018, and December 6, 2018, the Company entered into five $28,000 convertible promissory notes and four $33,000 convertible promissory notes with third parties for which the proceeds were used for operations. The Company received net proceeds of $245,000 and a $27,000 original issuance discount was recorded. The convertible promissory notes incur interest at 12% per annum for which $28,000 plus accrued interest were due on October 15, 2018, November 20, 2018, February 15, 2019, April 15, 2019 and May 30, 2019 and $33,000 plus accrued interest were due March 30, 2019, July 30, 2019, August 30, 2019, and September 30, 2019. The convertible promissory notes were convertible to shares of the Company's common stock 180 days after issuance. The conversion price per share was equal to 55% of the average of the three (3) lowest trading price of the Company's common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The Company had the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120 of 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes included various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. On January 2, 2019, February 7, 2019, March 11, 2019, April 23, 2019, August 28, 2019, October 30, 2019 and December 13, 2019, the Company entered into two $28,000 convertible promissory notes, three $33,000 convertible promissory notes, one $78,000 convertible promissory note and one $38,000 convertible promissory note with a third party for which the proceeds were used for operations. The Company received net proceeds of $250,000 and a $21,000 original issuance discount was recorded. The convertible promissory notes incur interest at 12% per annum for which $28,000 plus accrued interest are due on January 30, 2020 and October 30, 2020 and $33,000 plus accrued interest are/were due October 30, 2019, November 30, 2019 and February 28, 2020 and $78,000 plus accrued interest is due June 30, 2020 and $38,000 plus accrued interest is due June 30, 2020. The convertible promissory notes are convertible to shares of the Company's common stock 180 days after issuance. The conversion price per share is equal to 55% of the average of the three (3) lowest trading prices of the Company's common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The convertible proissory note dated February 7, 2019 was paid in full on July 26, 2019. The Company was required to reserve at December 31, 2019, a total of 872,670,108 common shares in connection with the promissory notes. Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the nine notes issued during the year ended December 31, 2018, the Company valued the conversion feature on the date of issuance resulting in initial liability of $633,121. Since the fair value of the derivatives were in excess of the proceeds received of $245,000, a full discount to convertible notes payable and a day one loss on derivative liabilities of $388,121 was recorded during the year ended December 31, 2018. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.002 to $0.006, the closing stock price of the Company's common stock on the date of valuation ranging from $0.0045 to $0.0220, an expected dividend yield of 0%, expected volatility ranging from 214% to 304%, risk-free interest rates ranging from 1.81% to 2.70%, and an expected term ranging from 0.76 to 0.82 years. During the year ended December 31, 2018, five of the $28,000 convertible notes and one of the $33,000 convertible notes were converted into 63,848,737 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2018, the Company recorded a gain of $165,563 related to the change of fair value of the derivative liability and recorded $311,509 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0033 to $0.005 the closing stock price of the Company's common stock on the date of valuation ranging from $0.0028 to $0.02720, an expected dividend yield of 0%, expected volatility ranging from 185% to 277%, risk-free interest rates ranging from 1.81% to 2.70%, and expected terms ranging from 0.07 to 0.75 years. On December 31, 2018, the derivative liabilities on the remaining five convertible notes were revalued at $466,612 resulting in a loss of $202,793 for the year ended December 31, 2018 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.002, the closing stock price of the Company's common stock on the date of valuation of $0.0055, an expected dividend yield of 0%, expected volatility ranging from 248% to 279%, risk-free interest rate of 2.63%, and an expected term ranging from 0.29 to 0.75 years. For the seven notes issued during the year ended December 31, 2019, the Company valued the conversion feature on the date of issuance resulting in initial liability of $602,934. Since the fair value of the derivatives were in excess of the proceeds received of $250,000, a full discount to convertible notes payable and a day one loss on derivative liabilities of $352,934 was recorded during the year ended December 31, 2019. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.001 to $0.003, the closing stock price of the Company's common stock on the date of valuation ranging from $0.002 to $0.009, an expected dividend yield of 0%, expected volatility ranging from 236% to 262%, risk-free interest rates ranging from 1.55% to 2.60%, and an expected term ranging from 0.81 to 1 years. During the year ended December 31, 2019, three of the $28,000 convertible notes and five of the $33,000 convertible notes were converted into 235,561,296 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended December 31, 2019, the Company recorded a gain of $310,347 related to the change of fair value of the derivative liability and recorded $498,324 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0004 to $0.002, the closing stock price of the Company's common stock on the date of valuation ranging from $0.001 to $0.009, an expected dividend yield of 0%, expected volatility ranging from 214% to 263%, risk-free interest rates ranging from 1.56% to 2.59%, and expected terms ranging from 0.26 to 0.38 years. On December 31, 2019, the derivative liabilities on the remaining three convertible notes were revalued at $521,700 resulting in a loss of $260,826 for the year ended December 31, 2019 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.001, the closing stock price of the Company's common stock on the date of valuation of $0.003, an expected dividend yield of 0%, expected volatility ranging from 245% to 262%, risk-free interest rate of 1.59%, and an expected term ranging from 0.5 to 0.95 years. The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2019 and 2018, the Company amortized $278,593 and $194,985 to interest expense, respectively. As of December 31, 2019, discounts of $105,525 remained for which will be amortized through December 2020.

Note 8 - Notes Payable - Relate

Note 8 - Notes Payable - Related Parties	12 Months Ended
	Dec. 31, 2019
Notes
Note 8 - Notes Payable - Related Parties	Note 8 – Notes payable-related parties Notes payable-related parties consist of: December 31, 2019 December 31, 2018 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 18,162 $ 17,015 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity date of December 31, 2019 37,671 138,105 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,700 - Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019 105,600 99,200 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004,respectively, with maturity date of April 20, 2019 246,334 204,167 942,467 458,487 Less debt discount (4,939) - $ 937,528 $ 458,487

Note 9 - Related party transact

Note 9 - Related party transactions	12 Months Ended
	Dec. 31, 2019
Notes
Note 9 - Related party transactions	Note 9 – Related party transactions As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $439,534 and $663,100, respectively. One of the officers settled with the company for a note payable that is unsecured and doesn’t accrue interest and will be paid as 0.5% of revenues. This decreased accrued officers’ salary. On October 25, 2018, we issued 15,000,000 shares of common stock, valued at $0.0071 each to two officers and one director of the Company under a Restricted Stock Award. On December 12, 2019, we issued 100,000,000 shares of common stock, valued at $0.0013 each to one officer and one director of the Company under a Restricted Stock Award.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes
Note 10 - Income Taxes	Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2019 December 31, 2018 Expected income tax at statutory rate $ (356,438) $ (391,884) State tax 168 168 Permanent differences 220,501 253,768 Other 6,556 (11,756) Change in valuation allowance 129,213 149,704 Provision for income taxes $ - $ - The significant components of deferred income tax assets and liabilities at December 31, 2019 and 2018 are as follows: December 31, 2019 December 31, 2018 Net operating loss carry-forward $ 1,450,896 $ 1,321,683 Valuation allowance (1,450,896) (1,321,683) Net deferred tax asset $ - $ - The Company has net operating losses carried forward of approximately $5.7 million and $5 million as of December 31, 2019 and 2018, respectively, available to offset taxable income in future years which expire beginning in fiscal 2032. As of and for the years ended December 31, 2019 and 2018, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2019 and 2018. The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2016. The Company currently is not under examination by any tax authority.

Note 11 - Equity

Note 11 - Equity	12 Months Ended
	Dec. 31, 2019
Notes
Note 11 - Equity	Note 11 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 shares, comprised of 3,500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of December 31, 2019, we have 1,614,627,811 shares of common stock and no preferred shares issued and outstanding. On January 26, 2018, we issued 2,424,242 shares of common stock for the partial conversion of $8,000 for convertible note dated July 24, 2017. On February 1, 2018, we issued 6,376,471 shares of common stock for the conversion of the balance of $20,000 for convertible note dated July 24, 2017. On February 1, 2018, we issued 5,000,000 shares of common stock, valued at $0.009 per share, for consulting services. On February 1, 2018, we issued 2,500,000 shares of common stock, valued at $0.009 per share, for consulting services. On February 20, 2018, we issued 15,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On February 20, 2018, we issued 2,500,000 shares of common stock, valued at $0.0062 per share, for consulting services. On April 14, 2018, we issued 2,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On April 14, 2018, we issued 5,000,000 shares of common stock, valued at $0.0057 per share, for consulting services. On April 27, 2018, we issued 3,225,806 shares of common stock for the partial conversion of $8,000 for convertible note dated September 7, 2017. On May 1, 2018, we issued 4,137,931 shares of common stock for the partial conversion of $12,000 for convertible note dated September 7, 2017. On May 2, 2018, we issued 25,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On May 21, 2018, we issued 2,742,857 shares of common stock for the partial conversion of $6,000 for convertible note dated September 7, 2017. On June 15, 2018, we issued 8,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement. On July 3, 2018, we issued 5,000,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement. On July 9, 2018, we issued 4,166,667 shares of common stock for the partial conversion of $15,000 for convertible note dated January 3, 2018. On July 12, 2018, we issued 4,077,778 shares of common stock for the partial conversion of $13,000 for convertible note dated January 3, 2018. On July 19, 2018, we issued 2,500,000 shares of common stock, valued at $0.015 per share, to a Scientific Advisory Board member for consulting services. On August 7, 2018, we issued 11,000,000 shares of common stock at $0.011 per share, for consulting services. On September 5, 2018, we issued 3,260,870 shares of common stock for the partial conversion of $15,000 for convertible note dated February 27, 2018. On September 10, 2018, we issued 3,262,222 shares of common stock for the partial conversion of $13,000 for convertible note dated February 27, 2018. On September 19, 2018, we issued 5,000,000 shares of common stock, valued at $0.005 per share, for an investment in the Company’s Private Placement. On September 19, 2018, we issued 1,500,000 shares of common stock, valued at $0.01 per share, to a Scientific Advisory Board member for consulting services. On October 25, 2018, we issued 15,000,000 shares of common stock, valued at .0071 each to two officers and one director of the Company under a Restricted Stock Award. On November 15, 2018, we issued 2,500,000 shares of common stock, valued at $0.008 per share, to a Scientific Advisory Board member for consulting services. On November 23, 2018, we issued 3,805,899 shares of common stock for the partial conversion of $12,000 for convertible note dated May 1, 2018. On November 26, 2018, we issued 4,347,826 shares of common stock for the partial conversion of $10,000 for convertible note dated May 1, 2018. On November 28, 2018, we issued 3,657,143 shares of common stock for the partial conversion of $6,000 for convertible note dated May 1, 2018. On December 7, 2018, we issued 8,823,529 shares of common stock for the partial conversion of $15,000 for convertible note dated June 5, 2018. On December 14, 2018, we issued 5,882,353 shares of common stock for the partial conversion of $10,000 for convertible note dated June 5, 2018. On December 17, 2018, we issued 5,870588 shares of common stock for the partial conversion of $8,000 for convertible note dated June 5, 2018. On January 3, 2019, we issued 15,000,000 shares of common stock, valued at $0.0071 each to two officers and one director of the Company under a Restricted Stock Award. On January 3, 2019, we issued 10,000,000 shares of common stock, valued at $0.005 per share, to a Scientific Advisory Board member for consulting services. On January 7, 2019, we issued 7,500,000 shares of common stock for the partial conversion of $12,000 for convertible note dated July 2, 2018. On January 9, 2019, we issued 6,250,000 shares of common stock for the partial conversion of $10,000 for convertible note dated July 2, 2018. On January 9, 2019, we issued 4,800,000 shares of common stock for the partial conversion of $7,680 for convertible note dated July 2, 2018. On February 8, 2019, we issued 8,333,333 shares of common stock for the partial conversion of $10,000 for convertible note dated August 6, 2018. On February 12, 2019, we issued 8,155,556 shares of common stock for the partial conversion of $14,680 for convertible note dated August 6, 2018. On April 15, 2019, we issued 6,000,000 shares of common stock for the partial conversion of $12,000 for convertible note dated October 3, 2018. On April 24, 2019, we issued 11,490,000 shares of common stock for the partial conversion of $22,980 for convertible note dated October 3, 2018. On May 20, 2019, we issued 6,666,667 shares of common stock for the partial conversion of $12,000 for convertible note dated November 15, 2018. On May 24, 2019, we issued 12,766,667 shares of common stock for the partial conversion of $22,980 for convertible note dated November 15, 2018. On June 11, 2019, we issued 21,818,182 shares of common stock for the partial conversion of $24,000 for convertible note dated December 6, 2018. On June 18, 2019, we issued 95,970,000 shares of common stock, valued at $0.0016 per share, for a license. On June 18, 2019, we issued 15,000,000 shares of common stock, valued at $0.0016 per share, to a Scientific Advisory Board member for consulting services. On June 19, 2019, we issued 12,200,000 shares of common stock for the partial conversion of $10,980 for convertible note dated December 6, 2018. On June 28, 2019, we issued 12,000,000 shares of common stock, valued at $0.0015 per share, for an investment in the Company’s Private Placement. On July 8, 2019, we issued 24,590,164 shares of common stock for the partial conversion of $15,000 for convertible note dated January 2, 2019. On July 11, 2019, we issued 32,754,098 shares of common stock for the partial conversion of $19,980 for convertible note dated January 2, 2019. On July 23, 2019, we issued 56,033,333 shares of common stock, valued at $0.0009 per share, for an investment in the Company’s Private Placement. On August 5, 2019, we issued 4,000,000 shares of common stock, valued at $0.002 per share, for an investment in the Company’s Private Placement. On September 12, 2019, we issued 10,000,000 shares of common stock for the partial conversion of $12,000 for convertible note dated March 11, 2019. On September 18, 2019, we issued 10,909,091 shares of common stock for the partial conversion of $12,000 for convertible note dated March 11, 2019. On September 20, 2019, we issued 5,737,374 shares of common stock for the partial conversion of $5,680 for convertible note dated March 11, 2019. On October 29, 2019, we issued 12,345,679 shares of common stock for the partial conversion of $10,000 for convertible note dated April 23, 2019. On October 31, 2019, we issued 18,987,342 shares of common stock for the partial conversion of $15,000 for convertible note dated April 23, 2019. On November 4, 2019, we issued 14,257,143 shares of common stock for the partial conversion of $9,980 for convertible note dated April 23, 2019. On December 12, 2019, we issued 30,000,000 shares of common stock, valued at $0.0013 per share, for consulting services. On December 12, 2019, we issued 100,000,000 shares of common stock, valued at $0.0013 each to one officer and one director of the Company under a Restricted Stock Award.

Note 12 - Legal proceedings

Note 12 - Legal proceedings	12 Months Ended
	Dec. 31, 2019
Notes
Note 12 - Legal proceedings	Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Notes
Note 13 - Commitments and Contingencies	Note 13 – Commitments and Contingencies Effective May 1, 2017, the Company entered into a fourth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2020. During the year ended December 31, 2019 and 2018, the Company incurred rent expense of $22,494 and $21,774. Future minimum lease payments as of December 31, 2019 are as follows: For the year ending December 31, 2020 $ 7,492 Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes
Note 14 - Subsequent Events	Note 14 – Subsequent events On February 3, 2020. we issued a annual convertible note in the amount of $33,000 with an annual interest rate of 12%. On March 1, 2020, the Company entered into a fifth amendment to the lease agreement for property located in Oceanside, CA. The amendment extends the expiration date to April 30, 2023 with escalating monthly payments ranging from $2,024 to $2,153. On March 2, 2020, we issued 8,333,333 shares of common stock for the partial conversion of $10,000 for the convertible note dated August 28, 2019. On March 5, 2020, we filed with the Nevada Secretary of State a Certificate of Amendment to Articles of Incorporation to effect an amendment (the “Amendment”) changing the number of authorized shares of our common stock to 3,500,000,000 (and changing the total number of authorized shares of stock to 3,505,000,000). On March 3, 2020, our stockholders acted by way of nonunanimous majority written consent action (pursuant to a solicitation of consents commenced on February 27, 2020, and in lieu of a special meeting of stockholders) to approve the Amendment. The number of shares giving written consent (i.e., voting) in favor of such matter was 927,629,005 (57.45%); no shares were overtly “voted against” the Amendment; and 686,998,806 shares did not participate in the nonunanimous majority written consent action (42.55%). On March 12, 2020, we issued 11,764,706 shares of common stock for the partial conversion of $10,000 for the convertible note dated August 28, 2019. On March 26, 2020, we issued 21,818,182 shares of common stock for the partial conversion of $12,000 for the convertible note dated August 28, 2019. In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2019 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Note 2 - Basis of Presentation_

Note 2 - Basis of Presentation: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Note 2 - Basis of Presentatio_2

Note 2 - Basis of Presentation: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) 2) 3) 4) 5) ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.

Note 2 - Basis of Presentatio_3

Note 2 - Basis of Presentation: Wholesale policies (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Wholesale policies	Wholesale policies: Delivery. Purchase Price & Payments. Inspection of Goods & Rejection. Risk of Loss.

Note 2 - Basis of Presentatio_4

Note 2 - Basis of Presentation: Retail policies of e-commerce (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Retail policies of e-commerce	Retail policies of e-commerce: Returns. Shipping. Out of Stock.

Note 2 - Basis of Presentatio_5

Note 2 - Basis of Presentation: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Note 2 - Basis of Presentatio_6

Note 2 - Basis of Presentation: Inventories (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Inventories	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.

Note 2 - Basis of Presentatio_7

Note 2 - Basis of Presentation: Derivative Liabilities (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2019 and 2018, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $521,700 and $466,612 at December 31, 2019 and 2018, respectively.

Note 2 - Basis of Presentatio_8

Note 2 - Basis of Presentation: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2018, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2019 and 2018: Balance, December 31, 2017 $ 107,769 Issuance of new derivative liabilities 633,122 Conversions to paid-in capital (311,509) Change in fair market value of derivative liabilities 37,230 Balance, December 31, 2018 466,612 Issuance of new derivative liabilities 602,934 Conversions to paid-in capital (498,325) Change in fair market value of derivative liabilities (49,521) Balance, December 31, 2019 $ 521,700

Note 2 - Basis of Presentatio_9

Note 2 - Basis of Presentation: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

Note 2 - Basis of Presentati_10

Note 2 - Basis of Presentation: Comprehensive Loss (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.

Note 2 - Basis of Presentati_11

Note 2 - Basis of Presentation: Net Loss Per Share (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2019 and 2018, a total of 181,588,903 and 226,902,346 ,

Note 2 - Basis of Presentati_12

Note 2 - Basis of Presentation: Depreciation and Amortization (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. During the years ended December 31, 2019 and 2018, there was no depreciation or amortization expense as all fixed assets have been fully depreciated.

Note 2 - Basis of Presentati_13

Note 2 - Basis of Presentation: Intangible Assets (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2019 and 2018 was $6,591 and $0, respectively.

Note 2 - Basis of Presentati_14

Note 2 - Basis of Presentation: Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

Note 2 - Basis of Presentati_15

Note 2 - Basis of Presentation: Research and Development (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $27,685 and $74,970 for the years ended December 31, 2019 and 2018, respectively.

Note 2 - Basis of Presentati_16

Note 2 - Basis of Presentation: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," "Accounting for Income Taxes" “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”

Note 2 - Basis of Presentati_17

Note 2 - Basis of Presentation: Stock-Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements.

Note 2 - Basis of Presentati_18

Note 2 - Basis of Presentation: Leases (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Leases	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $5,619 as of December 31, 2019.

Note 2 - Basis of Presentati_19

Note 2 - Basis of Presentation: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of the reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of adoption of this ASU and determined that it will have no significant impact on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. Changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the potential impact but does not believe there will be an impact of the adoption of this standard on its results of operations, financial position and cash flows and related disclosures.

Note 2 - Basis of Presentati_20

Note 2 - Basis of Presentation: Fair Value of Financial Instruments: Schedule of Change in Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Change in Derivative Liability	Balance, December 31, 2017 $ 107,769 Issuance of new derivative liabilities 633,122 Conversions to paid-in capital (311,509) Change in fair market value of derivative liabilities 37,230 Balance, December 31, 2018 466,612 Issuance of new derivative liabilities 602,934 Conversions to paid-in capital (498,325) Change in fair market value of derivative liabilities (49,521) Balance, December 31, 2019 $ 521,700

Note 4 - Prepaid expense and _2

Note 4 - Prepaid expense and other current assets: Schedule of Prepaid expenses and other current assets (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Prepaid expenses and other current assets	December 31, 2019 December 31, 2018 Prepaid consulting $ 88,261 $ 111,655 Insurance - 848 Prepaid costs 1,118 1,018 Total $ 89,379 $ 113,521

Note 5 - Fixed assets_ Property

Note 5 - Fixed assets: Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Property, Plant and Equipment	December 31, 2019 December 31, 2018 Computer hardware $ 10,747 $ 10,747 Office furniture and equipment 3,639 3,639 Shipping and other equipment 1,575 1,575 Total 15,961 15,961 Accumulated depreciation (15,961) (15,961) Property and equipment, net $ - $ -

Note 6 - Other Assets_ Schedule

Note 6 - Other Assets: Schedule of Other Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Other Assets	December 31, 2019 December 31, 2018 Prepaid consulting $ 20,238 $ 56,717 Deposit 4,123 4,123 Licenses, net 146,961 - Total $ 171,322 $ 60,840

Note 6 - Other Assets_ Schedu_2

Note 6 - Other Assets: Schedule of net licenses (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of net licenses	December 31, 2019 December 31, 2018 License $ 153,552 $ - Accumulated amortization (6,591) - Licenses, net $ 146,961 $ -

Note 8 - Notes Payable - Rela_2

Note 8 - Notes Payable - Related Parties: Notes payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Notes payable, Related Parties	December 31, 2019 December 31, 2018 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 18,162 $ 17,015 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity date of December 31, 2019 37,671 138,105 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,700 - Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019 105,600 99,200 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004,respectively, with maturity date of April 20, 2019 246,334 204,167 942,467 458,487 Less debt discount (4,939) - $ 937,528 $ 458,487

Note 10 - Income Taxes_ Schedul

Note 10 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	December 31, 2019 December 31, 2018 Expected income tax at statutory rate $ (356,438) $ (391,884) State tax 168 168 Permanent differences 220,501 253,768 Other 6,556 (11,756) Change in valuation allowance 129,213 149,704 Provision for income taxes $ - $ -

Note 10 - Income Taxes_ Sched_2

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	December 31, 2019 December 31, 2018 Net operating loss carry-forward $ 1,450,896 $ 1,321,683 Valuation allowance (1,450,896) (1,321,683) Net deferred tax asset $ - $ -

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Future Minimum Lease Payments	For the year ending December 31, 2020 $ 7,492

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details)	12 Months Ended
	Dec. 31, 2019
Details
Entity Incorporation, Date of Incorporation	Aug. 6, 2007
Entity Incorporation, State or Country Code	NV

Note 2 - Basis of Presentati_21

Note 2 - Basis of Presentation: Derivative Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Derivative Liability, Current	$ 521,700	$ 466,612

Note 2 - Basis of Presentati_22

Note 2 - Basis of Presentation: Fair Value of Financial Instruments: Schedule of Change in Derivative Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Balance, December 31, 2017	$ 466,612	$ 107,769
Issuance of new derivative liabilities	602,934	633,122
Conversions to paid-in capital		(311,509)
Change in fair market value of derivative liabilities	(49,521)	37,230
Balance, December 31, 2018	521,700	$ 466,612
Conversions to paid-in capital	$ (498,325)

Note 2 - Basis of Presentati_23

Note 2 - Basis of Presentation: Net Loss Per Share (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Details
Antidilutive Common Shares Excluded from EPS calculation	181,588,903	226,902,346

Note 2 - Basis of Presentati_24

Note 2 - Basis of Presentation: Depreciation and Amortization (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Depreciation	$ 0	$ 0
Amortization of Acquisition Costs	$ 0	$ 0

Note 3 - Restricted Cash (Detai

Note 3 - Restricted Cash (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Details
Restricted Cash, Current	$ 10,000
Restricted Cash, Current, Nature of Restriction, Description	used as collateral for a Company credit card

Note 4 - Prepaid expense and _3

Note 4 - Prepaid expense and other current assets: Schedule of Prepaid expenses and other current assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Prepaid Consulting	$ 88,261	$ 111,655
Insurance	0	848
Prepaid costs	1,118	1,018
Prepaid expenses and other current assets	$ 89,379	$ 113,521

Note 5 - Fixed assets_ Proper_2

Note 5 - Fixed assets: Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Computer Equipment
Property, Plant and Equipment, Gross	$ 10,747	$ 10,747
Office Equipment
Property, Plant and Equipment, Gross	3,639	3,639
Other Transportation Equipment
Property, Plant and Equipment, Gross	1,575	1,575
Property, Plant and Equipment, Gross	15,961	15,961
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(15,961)	(15,961)
Property, Plant and Equipment, Net	$ 0	$ 0

Note 5 - Fixed assets (Details)

Note 5 - Fixed assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Depreciation	$ 0	$ 0

Note 6 - Other Assets_ Schedu_3

Note 6 - Other Assets: Schedule of Other Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Prepaid Consulting	$ 20,238	$ 56,717
Deposit	4,123	4,123
Licenses, net	146,961	0
Assets, Noncurrent	$ 171,322	$ 60,840

Note 6 - Other Assets_ Schedu_4

Note 6 - Other Assets: Schedule of net licenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
License	$ 153,552	$ 0
Accumulated amortization	(6,591)	0
Licenses, net	$ 146,961	$ 0

Note 7 - Convertible Notes Pa_2

Note 7 - Convertible Notes Payable (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)	Jun. 30, 2019$ / shares
Share Price			$ 0.015
Amortization to Interest Expense | $	$ 278,593	$ 194,985
Discount Balance remaining to be amortized | $	$ 105,525
Conversion feature
Fair Value Assumptions, Expected Dividend Rate	0
Conversion feature | Minimum
Fair Value Assumptions, Conversion Price	$ 0.002
Share Price	$ 0.0045
Fair Value Assumptions, Expected Volatility Rate	2.1400
Fair Value Assumptions, Risk Free Interest Rate	0.0181
Fair Value Assumptions, Expected Term	9 months 4 days
Conversion feature | Maximum
Fair Value Assumptions, Conversion Price	$ 0.006
Share Price	$ 0.0220
Fair Value Assumptions, Expected Volatility Rate	3.0400
Fair Value Assumptions, Risk Free Interest Rate	0.0270
Fair Value Assumptions, Expected Term	9 months 25 days
Revalued Derivative Liabilities
Fair Value Assumptions, Conversion Price	$ 0.002
Share Price	$ 0.0055
Fair Value Assumptions, Expected Dividend Rate	0
Fair Value Assumptions, Risk Free Interest Rate	0.0263
Revalued Derivative Liabilities | Minimum
Fair Value Assumptions, Expected Volatility Rate	2.4800
Fair Value Assumptions, Expected Term	3 months 14 days
Revalued Derivative Liabilities | Maximum
Fair Value Assumptions, Expected Volatility Rate	2.7900
Fair Value Assumptions, Expected Term	9 months
Convertible Notes #1
Debt Instrument, Description	Company entered into five $28,000 convertible promissory notes and four $33,000 convertible promissory notes with third parties for which the proceeds were used for operations
Proceeds from Loans | $	$ 245,000
Debt Instrument, Unamortized Discount | $	$ 27,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	convertible to shares of the Company's common stock 180 days after issuance
Convertible Notes #2
Debt Instrument, Description	Company entered into two $28,000 convertible promissory notes, three $33,000 convertible promissory notes, one $78,000 convertible promissory note and one $38,000 convertible promissory note with a third party for which the proceeds were used for operations
Proceeds from Loans | $	$ 250,000
Debt Instrument, Unamortized Discount | $	$ 21,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	convertible to shares of the Company's common stock 180 days after issuance

Note 8 - Notes Payable - Rela_3

Note 8 - Notes Payable - Related Parties: Notes payable, Related Parties (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Note payable - Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2018
Long-term Debt, Gross	$ 18,162	$ 17,015
Three notes payable - Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2018.
Long-term Debt, Gross	37,671	138,105
One note payable - Chief Executive Officer, unsecured, no interest, paid from a % of revenues
Long-term Debt, Gross	534,700	0
Note payable - Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2018,
Long-term Debt, Gross	105,600	99,200
Two notes payable - Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity dates of April 20, 2018
Long-term Debt, Gross	246,334	204,167
Long-term Debt, Gross	942,467	458,487
Less debt discount	(4,939)	0
Long-term Debt, Net	$ 937,528	$ 458,487

Note 9 - Related party transa_2

Note 9 - Related party transactions (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Related Party Transaction #1
Sale of Stock, Transaction Date	Oct. 25, 2018
Stock Issued During Period, Shares, New Issues | shares	15,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0071
Related Party Transaction #2
Sale of Stock, Transaction Date	Dec. 12, 2019
Stock Issued During Period, Shares, New Issues | shares	100,000,000
Sale of Stock, Price Per Share | $ / shares	$ 0.0013

Note 10 - Income Taxes_ Sched_3

Note 10 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Expected income tax at statutory rate	$ (356,438)	$ (391,884)
State Tax	168	168
Permanent differences	220,501	253,768
Other	6,556	(11,756)
Change in valuation allowance	129,213	149,704
Provision for income taxes	$ 0	$ 0

Note 10 - Income Taxes_ Sched_4

Note 10 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Net operating loss carry-forward	$ 1,450,896	$ 1,321,683
Valuation allowance	(1,450,896)	(1,321,683)
Net deferred tax asset	$ 0	$ 0

Note 11 - Equity (Details)

Note 11 - Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Common Stock, Shares Authorized	3,500,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Shares, Issued	1,614,627,811	1,011,063,182
Common Stock, Shares, Outstanding	1,614,627,811	1,011,063,182
Preferred Stock, Shares Issued	0
Preferred Stock, Shares Outstanding	0
Sale of Stock Transaction 1
Sale of Stock, Transaction Date	Jan. 26, 2018
Stock Issued During Period, Shares, New Issues	2,424,242
Stock Issued	$ 8,000
Sale of Stock Transaction 2
Sale of Stock, Transaction Date	Feb. 1, 2018
Stock Issued During Period, Shares, New Issues	6,376,471
Stock Issued	$ 20,000
Sale of Stock Transaction 3
Sale of Stock, Transaction Date	Feb. 1, 2018
Stock Issued During Period, Shares, New Issues	5,000,000
Sale of Stock, Price Per Share	$ 0.009
Sale of Stock Transaction 4
Sale of Stock, Transaction Date	Feb. 1, 2018
Stock Issued During Period, Shares, New Issues	2,500,000
Sale of Stock, Price Per Share	$ 0.009
Sale of Stock Transaction 5
Sale of Stock, Transaction Date	Feb. 20, 2018
Stock Issued During Period, Shares, New Issues	15,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 6
Sale of Stock, Transaction Date	Feb. 20, 2018
Stock Issued During Period, Shares, New Issues	2,500,000
Sale of Stock, Price Per Share	$ 0.0062
Sale of Stock Transaction 7
Sale of Stock, Transaction Date	Apr. 14, 2018
Stock Issued During Period, Shares, New Issues	2,500,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 8
Sale of Stock, Transaction Date	Apr. 14, 2018
Stock Issued During Period, Shares, New Issues	5,000,000
Sale of Stock, Price Per Share	$ 0.0057
Sale of Stock Transaction 9
Sale of Stock, Transaction Date	Apr. 27, 2018
Stock Issued During Period, Shares, New Issues	3,225,806
Stock Issued	$ 8,000
Sale of Stock Transaction 10
Sale of Stock, Transaction Date	May 1, 2018
Stock Issued During Period, Shares, New Issues	4,137,931
Stock Issued	$ 12,000
Sale of Stock Transaction 11
Sale of Stock, Transaction Date	May 2, 2018
Stock Issued During Period, Shares, New Issues	25,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 12
Sale of Stock, Transaction Date	May 21, 2018
Stock Issued During Period, Shares, New Issues	2,742,857
Stock Issued	$ 6,000
Sale of Stock Transaction 13
Sale of Stock, Transaction Date	Jun. 15, 2018
Stock Issued During Period, Shares, New Issues	8,500,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 14
Sale of Stock, Transaction Date	Jul. 3, 2018
Stock Issued During Period, Shares, New Issues	5,000,000
Sale of Stock, Price Per Share	$ 0.004
Sale of Stock Transaction 15
Sale of Stock, Transaction Date	Jul. 9, 2018
Stock Issued During Period, Shares, New Issues	4,166,667
Stock Issued	$ 15,000
Sale of Stock Transaction 16
Sale of Stock, Transaction Date	Jul. 12, 2018
Stock Issued During Period, Shares, New Issues	4,077,778
Stock Issued	$ 13,000
Sale of Stock Transaction 17
Sale of Stock, Transaction Date	Jul. 19, 2018
Stock Issued During Period, Shares, New Issues	2,500,000
Sale of Stock, Price Per Share	$ 0.015
Sale of Stock Transaction 18
Sale of Stock, Transaction Date	Aug. 7, 2018
Stock Issued During Period, Shares, New Issues	11,000,000
Sale of Stock, Price Per Share	$ 0.011
Sale of Stock Transaction 19
Sale of Stock, Transaction Date	Sep. 5, 2018
Stock Issued During Period, Shares, New Issues	3,260,870
Stock Issued	$ 15,000
Sale of Stock Transaction 20
Sale of Stock, Transaction Date	Sep. 10, 2018
Stock Issued During Period, Shares, New Issues	3,262,222
Stock Issued	$ 13,000
Sale of Stock Transaction 21
Sale of Stock, Transaction Date	Sep. 19, 2018
Stock Issued During Period, Shares, New Issues	5,000,000
Sale of Stock, Price Per Share	$ 0.005
Sale of Stock Transaction 22
Sale of Stock, Transaction Date	Sep. 19, 2018
Stock Issued During Period, Shares, New Issues	1,500,000
Sale of Stock, Price Per Share	$ 0.01
Sale of Stock Transaction 23
Sale of Stock, Transaction Date	Oct. 25, 2018
Stock Issued During Period, Shares, New Issues	15,000,000
Sale of Stock, Price Per Share	$ 71
Sale of Stock Transaction 24
Sale of Stock, Transaction Date	Nov. 15, 2018
Stock Issued During Period, Shares, New Issues	2,500,000
Sale of Stock, Price Per Share	$ 0.008
Sale of Stock Transaction 25
Sale of Stock, Transaction Date	Nov. 23, 2018
Stock Issued During Period, Shares, New Issues	3,805,899
Stock Issued	$ 12,000
Sale of Stock Transaction 26
Sale of Stock, Transaction Date	Nov. 26, 2018
Stock Issued During Period, Shares, New Issues	4,347,826
Stock Issued	$ 10,000
Sale of Stock Transaction 27
Sale of Stock, Transaction Date	Nov. 28, 2018
Stock Issued During Period, Shares, New Issues	3,657,143
Stock Issued	$ 6,000
Sale of Stock Transaction 28
Sale of Stock, Transaction Date	Dec. 7, 2018
Stock Issued During Period, Shares, New Issues	8,823,529
Stock Issued	$ 15,000
Sale of Stock Transaction 29
Sale of Stock, Transaction Date	Dec. 14, 2018
Stock Issued During Period, Shares, New Issues	5,882,353
Stock Issued	$ 10,000
Sale of Stock Transaction 30
Sale of Stock, Transaction Date	Dec. 17, 2018
Stock Issued During Period, Shares, New Issues	5,870,588
Stock Issued	$ 8,000
Sale of Stock Transaction 31
Sale of Stock, Transaction Date	Jan. 3, 2019
Stock Issued During Period, Shares, New Issues	15,000,000
Sale of Stock, Price Per Share	$ 0.0071
Sale of Stock Transaction 32
Sale of Stock, Transaction Date	Jan. 3, 2019
Stock Issued During Period, Shares, New Issues	10,000,000
Sale of Stock, Price Per Share	$ 0.005
Sale of Stock Transaction 33
Sale of Stock, Transaction Date	Jan. 7, 2019
Stock Issued During Period, Shares, New Issues	7,500,000
Stock Issued	$ 12,000
Sale of Stock Transaction 34
Sale of Stock, Transaction Date	Jan. 9, 2019
Stock Issued During Period, Shares, New Issues	6,250,000
Stock Issued	$ 10,000
Sale of Stock Transaction 35
Sale of Stock, Transaction Date	Jan. 9, 2019
Stock Issued During Period, Shares, New Issues	4,800,000
Stock Issued	$ 7,680
Sale of Stock Transaction 36
Sale of Stock, Transaction Date	Feb. 8, 2019
Stock Issued During Period, Shares, New Issues	8,333,333
Stock Issued	$ 10,000
Sale of Stock Transaction 37
Sale of Stock, Transaction Date	Feb. 12, 2019
Stock Issued During Period, Shares, New Issues	8,155,556
Stock Issued	$ 14,680
Sale of Stock Transaction 38
Sale of Stock, Transaction Date	Apr. 15, 2019
Stock Issued During Period, Shares, New Issues	6,000,000
Stock Issued	$ 12,000
Sale of Stock Transaction 39
Sale of Stock, Transaction Date	Apr. 24, 2019
Stock Issued During Period, Shares, New Issues	11,490,000
Stock Issued	$ 22,980
Sale of Stock Transaction 40
Sale of Stock, Transaction Date	May 20, 2019
Stock Issued During Period, Shares, New Issues	6,666,667
Stock Issued	$ 12,000
Sale of Stock Transaction 41
Sale of Stock, Transaction Date	May 24, 2019
Stock Issued During Period, Shares, New Issues	12,766,667
Stock Issued	$ 22,980
Sale of Stock Transaction 42
Sale of Stock, Transaction Date	Jun. 11, 2019
Stock Issued During Period, Shares, New Issues	21,818,182
Stock Issued	$ 24,000
Sale of Stock Transaction 43
Sale of Stock, Transaction Date	Jun. 18, 2019
Stock Issued During Period, Shares, New Issues	95,970,000
Sale of Stock, Price Per Share	$ 0.0016
Sale of Stock Transaction 44
Sale of Stock, Transaction Date	Jun. 18, 2019
Stock Issued During Period, Shares, New Issues	15,000,000
Sale of Stock, Price Per Share	$ 0.0016
Sale of Stock Transaction 45
Sale of Stock, Transaction Date	Jun. 19, 2019
Stock Issued During Period, Shares, New Issues	12,200,000
Stock Issued	$ 10,980
Sale of Stock Transaction 46
Sale of Stock, Transaction Date	Jun. 28, 2019
Stock Issued During Period, Shares, New Issues	12,000,000
Sale of Stock, Price Per Share	$ 0.0015
Sale of Stock Transaction 47
Sale of Stock, Transaction Date	Jul. 8, 2019
Stock Issued During Period, Shares, New Issues	24,590,164
Stock Issued	$ 15,000
Sale of Stock Transaction 48
Sale of Stock, Transaction Date	Jul. 11, 2019
Stock Issued During Period, Shares, New Issues	32,754,098
Stock Issued	$ 19,980
Sale of Stock Transaction 49
Sale of Stock, Transaction Date	Jul. 23, 2019
Stock Issued During Period, Shares, New Issues	56,033,333
Sale of Stock, Price Per Share	$ 0.0009
Sale of Stock Transaction 50
Sale of Stock, Transaction Date	Aug. 5, 2019
Stock Issued During Period, Shares, New Issues	4,000,000
Sale of Stock, Price Per Share	$ 0.002
Sale of Stock Transaction 51
Sale of Stock, Transaction Date	Sep. 12, 2019
Stock Issued During Period, Shares, New Issues	10,000,000
Stock Issued	$ 12,000
Sale of Stock Transaction 52
Sale of Stock, Transaction Date	Sep. 18, 2019
Stock Issued During Period, Shares, New Issues	10,909,091
Stock Issued	$ 12,000
Sale of Stock Transaction 53
Sale of Stock, Transaction Date	Sep. 20, 2019
Stock Issued During Period, Shares, New Issues	5,737,374
Stock Issued	$ 5,680
Sale of Stock Transaction 54
Sale of Stock, Transaction Date	Oct. 29, 2019
Stock Issued During Period, Shares, New Issues	12,345,679
Stock Issued	$ 10,000
Sale of Stock Transaction 55
Sale of Stock, Transaction Date	Oct. 31, 2019
Stock Issued During Period, Shares, New Issues	18,987,342
Stock Issued	$ 15,000
Sale of Stock Transaction 56
Sale of Stock, Transaction Date	Nov. 4, 2019
Stock Issued During Period, Shares, New Issues	14,257,143
Stock Issued	$ 9,980
Sale of Stock Transaction 57
Sale of Stock, Transaction Date	Dec. 12, 2019
Stock Issued During Period, Shares, New Issues	30,000,000
Sale of Stock, Price Per Share	$ 0.0013
Sale of Stock Transaction 58
Sale of Stock, Transaction Date	Dec. 12, 2019
Stock Issued During Period, Shares, New Issues	100,000,000
Sale of Stock, Price Per Share	$ 0.0013

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Payments for Rent	$ 22,494	$ 21,774

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2019USD ($)
Details
Operating Leases, Future Minimum Payments, Due in Two Years	$ 7,492

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details)	12 Months Ended
	Dec. 31, 2019USD ($)shares
Event 1
Subsequent Event, Date	Feb. 3, 2020
Subsequent Event, Description	we issued a annual convertible note
Debt Instrument, Description	annual convertible note
Debt Instrument, Face Amount	$ 33,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Event 2
Subsequent Event, Date	Mar. 1, 2020
Subsequent Event, Description	Company entered into a fifth amendment to the lease agreement for property located in Oceanside, CA
Event 3
Subsequent Event, Date	Mar. 2, 2020
Subsequent Event, Description	we issued 8,333,333 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	8,333,333
Stock Issued	$ 10,000
Event 4
Subsequent Event, Date	Mar. 5, 2020
Subsequent Event, Description	we filed with the Nevada Secretary of State a Certificate of Amendment to Articles of Incorporation to effect an amendment (the “Amendment”) changing the number of authorized shares of our common stock
Event 5
Subsequent Event, Date	Mar. 3, 2020
Subsequent Event, Description	our stockholders acted by way of nonunanimous majority written consent action (pursuant to a solicitation of consents commenced on February 27, 2020, and in lieu of a special meeting of stockholders) to approve the Amendment
Event 6
Subsequent Event, Date	Mar. 12, 2020
Subsequent Event, Description	we issued 11,764,706 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	11,764,706
Stock Issued	$ 10,000
Event 7
Subsequent Event, Date	Mar. 26, 2020
Subsequent Event, Description	we issued 21,818,182 shares of common stock
Stock Issued During Period, Shares, New Issues | shares	21,818,182
Stock Issued	$ 12,000